Envista Holdings Corp (NVST) · Insider trading
What Envista Holdings's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$510,250
1 insider, 100% under a plan
Net, 12 months
−$510,250
bought less sold
Latest filing
2026-08-27
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Reis MischaSVP, Strategy & Bus. Dev. | – | $834,250 | 4 | 2026-08-20 | 27,321 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Reis MischaSVP, Strategy & Bus. Dev. | Saleplan | 8,000 | 27.50 | $220,000 | 27,321 | Form 4 |
| 2026-02-10 | Reis MischaSVP, Strategy & Bus. Dev. | Saleplan | 4,041 | 30.00 | $121,230 | 32,382 | Form 4 |
| 2026-02-10 | Reis MischaSVP, Strategy & Bus. Dev. | Saleplan | 5,634 | 30.00 | $169,020 | 32,382 | Form 4 |
| 2025-08-25 | Reis MischaSVP, Strategy & Bus. Dev. | Saleplan | 15,000 | 21.60 | $324,000 | 32,382 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
32 × grant or award24 × shares withheld for tax2 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-25 | Hammes Eric D.Chief Financial Officer | Shares withheld for tax F | −10,885 | 27.47 | 99,913 | Form 4 |
| 2026-08-25 | Befidi RobertPresident, Diagnostics | Shares withheld for tax F | −5,147 | 27.47 | 45,785 | Form 4 |
| 2026-08-25 | Nilsson StefanPresident, Nobel Biocare | Shares withheld for tax F | −804 | 27.47 | 61,560 | Form 4 |
| 2026-08-25 | Acurio VeronicaPresident, Orthodontics | Shares withheld for tax F | −7,710 | 27.47 | 48,806 | Form 4 |
| 2026-08-18 | Keel Paul ADirector, Chief Executive Officer | Grant or award A | +179,730 | – | 551,304 | Form 4 |
| 2026-05-25 | Keel Paul ADirector, Chief Executive Officer | Shares withheld for tax F | −12,811 | 23.43 | 371,574 | Form 4 |
| 2026-05-19 | Tsingos Christine ADirector | Grant or award A | +9,330 | – | 59,930 | Form 4 |
| 2026-05-19 | Raskas DanielDirector | Grant or award A | +9,330 | – | 54,010 | Form 4 |
| 2026-05-19 | Gallahue KieranDirector | Grant or award A | +9,330 | – | 54,010 | Form 4 |
| 2026-05-19 | Huennekens R ScottDirector | Grant or award A | +12,585 | – | 82,105 | Form 4 |
| 2026-05-19 | Jain VivekDirector | Grant or award A | +9,330 | – | 52,945 | Form 4 |
| 2026-05-19 | Carruthers WendyDirector | Grant or award A | +9,330 | – | 59,940 | Form 4 |
| 2026-05-19 | Pierce James AndrewDirector | Grant or award A | +9,330 | – | 18,485 | Form 4 |
| 2026-02-25 | Hammes Eric D.Chief Financial Officer | Shares withheld for tax F | −2,045 | 29.59 | 94,743 | Form 4 |
| 2026-02-25 | Hammes Eric D.Chief Financial Officer | Grant or award A | +16,055 | – | 110,798 | Form 4 |
| 2026-02-25 | Keel Paul ADirector, Chief Executive Officer | Shares withheld for tax F | −11,840 | 29.59 | 335,715 | Form 4 |
| 2026-02-25 | Keel Paul ADirector, Chief Executive Officer | Grant or award A | +48,670 | – | 384,385 | Form 4 |
| 2026-02-25 | Nance Mark EGeneral Counsel | Shares withheld for tax F | −3,368 | 29.59 | 68,577 | Form 4 |
| 2026-02-25 | Nance Mark EGeneral Counsel | Grant or award A | +12,675 | – | 81,252 | Form 4 |
| 2026-02-25 | Reis MischaSVP, Strategy & Bus. Dev. | Shares withheld for tax F | −2,976 | 29.59 | 29,406 | Form 4 |
| 2026-02-25 | Reis MischaSVP, Strategy & Bus. Dev. | Grant or award A | +5,915 | – | 35,321 | Form 4 |
| 2026-02-25 | Kaabi Faez CChief Accounting Officer | Shares withheld for tax F | −4,964 | 29.59 | 45,032 | Form 4 |
| 2026-02-25 | Kaabi Faez CChief Accounting Officer | Grant or award A | +13,520 | – | 58,552 | Form 4 |
| 2026-02-25 | Befidi RobertPresident, Diagnostics | Shares withheld for tax F | −2,177 | 29.59 | 43,327 | Form 4 |
| 2026-02-25 | Befidi RobertPresident, Diagnostics | Grant or award A | +7,605 | – | 50,932 | Form 4 |
| 2026-02-25 | Nilsson StefanPresident, Nobel Biocare | Shares withheld for tax F | −182 | 29.59 | 54,759 | Form 4 |
| 2026-02-25 | Nilsson StefanPresident, Nobel Biocare | Grant or award A | +7,605 | – | 62,364 | Form 4 |
| 2026-02-25 | Acurio VeronicaPresident, Orthodontics | Shares withheld for tax F | −1,412 | 29.59 | 48,911 | Form 4 |
| 2026-02-25 | Acurio VeronicaPresident, Orthodontics | Grant or award A | +7,605 | – | 56,516 | Form 4 |
| 2026-02-10 | Reis MischaSVP, Strategy & Bus. Dev. | Option exercise M | +4,041 | 19.04 | 36,423 | Form 4 |
| 2026-02-10 | Reis MischaSVP, Strategy & Bus. Dev. | Option exercise M | +5,634 | 15.97 | 38,016 | Form 4 |
| 2025-11-01 | Keel Paul ADirector, Chief Executive Officer | Shares withheld for tax F | −54,097 | 20.35 | 347,555 | Form 4 |
| 2025-08-25 | Hammes Eric D.Chief Financial Officer | Shares withheld for tax F | −7,654 | 21.12 | 96,788 | Form 4 |
| 2025-08-25 | Befidi RobertPresident, Diagnostics | Shares withheld for tax F | −3,454 | 21.12 | 45,504 | Form 4 |
| 2025-08-25 | Nilsson StefanPresident, Nobel Biocare | Shares withheld for tax F | −804 | 21.12 | 54,941 | Form 4 |
| 2025-08-25 | Acurio VeronicaPresident, Orthodontics | Shares withheld for tax F | −5,422 | 21.12 | 50,323 | Form 4 |
| 2025-07-14 | Pierce James AndrewDirector | Grant or award A | +9,155 | – | 9,155 | Form 4 |
| 2025-06-10 | Huennekens R ScottDirector | Grant or award A | +14,370 | – | 69,520 | Form 4 |
| 2025-06-10 | Hulit Barbara B.Director | Grant or award A | +10,450 | – | 79,820 | Form 4 |
| 2025-06-10 | Tsingos Christine ADirector | Grant or award A | +10,450 | – | 50,600 | Form 4 |
| 2025-06-10 | Carruthers WendyDirector | Grant or award A | +10,450 | – | 50,610 | Form 4 |
| 2025-06-10 | Jain VivekDirector | Grant or award A | +10,450 | – | 43,615 | Form 4 |
| 2025-06-10 | Raskas DanielDirector | Grant or award A | +10,450 | – | 44,680 | Form 4 |
| 2025-06-10 | Gallahue KieranDirector | Grant or award A | +10,450 | – | 44,680 | Form 4 |
| 2025-05-25 | Keel Paul ADirector, Chief Executive Officer | Shares withheld for tax F | −12,787 | 16.72 | 401,652 | Form 4 |
| 2025-02-26 | Reis MischaSVP, Strategy & Bus. Dev. | Grant or award A | +8,475 | – | 47,382 | Form 4 |
| 2025-02-25 | Nance Mark EGeneral Counsel | Shares withheld for tax F | −3,691 | 20.66 | 53,790 | Form 4 |
| 2025-02-25 | Nance Mark EGeneral Counsel | Grant or award A | +18,155 | – | 71,945 | Form 4 |
| 2025-02-25 | Hammes Eric D.Chief Financial Officer | Grant or award A | +15,735 | – | 104,442 | Form 4 |
| 2025-02-25 | Befidi RobertPresident, Diagnostics | Shares withheld for tax F | −1,123 | 20.66 | 38,668 | Form 4 |
| 2025-02-25 | Befidi RobertPresident, Diagnostics | Grant or award A | +10,290 | – | 48,958 | Form 4 |
| 2025-02-25 | Nilsson StefanPresident, Nobel Biocare | Grant or award A | +10,290 | – | 55,745 | Form 4 |
| 2025-02-25 | Acurio VeronicaPresident, Orthodontics | Grant or award A | +10,290 | – | 55,745 | Form 4 |
| 2025-02-25 | Keel Paul ADirector, Chief Executive Officer | Grant or award A | +65,830 | – | 414,439 | Form 4 |
| 2025-02-25 | Reis MischaSVP, Strategy & Bus. Dev. | Shares withheld for tax F | −3,813 | 20.66 | 38,907 | Form 4 |
| 2025-02-25 | Kaabi Faez CChief Accounting Officer | Shares withheld for tax F | −4,319 | 20.66 | 40,311 | Form 4 |
| 2025-02-25 | Kaabi Faez CChief Accounting Officer | Grant or award A | +9,685 | – | 49,996 | Form 4 |
| 2024-11-01 | Keel Paul ADirector, Chief Executive Officer | Shares withheld for tax F | −53,996 | 20.94 | 348,609 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.